About bausch & lomb corp - BLCO
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.
BLCO At a Glance
Bausch + Lomb Corp.
520 Applewood Crescent
Vaughan, Ontario L4K 4B4
| Phone | 1-905-695-7700 | Revenue | 5.10B | |
| Industry | Medical Specialties | Net Income | -360,000,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 6.47% | |
| Fiscal Year-end | 12 / 2026 | Employees | 13,000 | |
| View SEC Filings |
BLCO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.187 |
| Price to Book Ratio | 0.94 |
| Price to Cash Flow Ratio | 21.39 |
| Enterprise Value to EBITDA | 18.016 |
| Enterprise Value to Sales | 2.151 |
| Total Debt to Enterprise Value | 0.478 |
BLCO Efficiency
| Revenue/Employee | 392,384.615 |
| Income Per Employee | -27,692.308 |
| Receivables Turnover | 4.174 |
| Total Asset Turnover | 0.371 |
BLCO Liquidity
| Current Ratio | 1.551 |
| Quick Ratio | 1.042 |
| Cash Ratio | 0.207 |
BLCO Profitability
| Gross Margin | 54.754 |
| Operating Margin | 3.686 |
| Pretax Margin | -6.214 |
| Net Margin | -7.057 |
| Return on Assets | -2.619 |
| Return on Equity | -5.572 |
| Return on Total Capital | -3.079 |
| Return on Invested Capital | -3.137 |
BLCO Capital Structure
| Total Debt to Total Equity | 81.343 |
| Total Debt to Total Capital | 44.856 |
| Total Debt to Total Assets | 37.406 |
| Long-Term Debt to Equity | 80.149 |
| Long-Term Debt to Total Capital | 44.197 |